Ocugen (MEX:OCGN) Institutional Ownership : 19.19% (As of Apr. 19, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Ocugen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ocugen's institutional ownership is 19.19%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ocugen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ocugen's Float Percentage Of Total Shares Outstanding is 98.34%.

Ocugen Institutional Ownership Historical Data

The historical data trend for Ocugen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Institutional Ownership Chart

Ocugen Historical Data

The historical data trend for Ocugen can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Institutional Ownership	20.77	23.49	21.52	23.00	22.84	23.06	19.72	19.60	19.38	19.19

Ocugen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Ocugen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (MEX:OCGN) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

OCGN:USA 2H51:Germany

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").